Pulmonary Edema Therapeutics Market is Driven by Increasing Prevalence of Cardiovascular Diseases
![]() |
Pulmonary Edema Therapeutics Market |
Pulmonary
edema refers to the abnormal accumulation of fluid in the air sacs of the lungs
known as alveoli. It is caused by disorders like congestive heart failure,
kidney failure, acute lung injury etc. that damage or weaken the blood vessels
in the lungs. Treatment of pulmonary edema involves reducing fluid retention
and improving heart or kidney function. Therapeutics include diuretics,
vasodilators, inotropic agents, antibiotics, oxygen therapy etc. depending on
the underlying condition. The global Pulmonary Edema Therapeutics market is
dominated by diuretics that aid fluid removal from the lungs and tissues. The
need for pulmonary edema therapeutics is driven by the growing prevalence of
cardiovascular diseases worldwide which can weaken heart muscles leading to
congestive heart failure and pulmonary edema.
The
global Pulmonary Edema Therapeutics Market is estimated to be valued at US$
13990.01 Bn in 2024 and is expected to exhibit a CAGR of 9.8% over the forecast
period 2024 to 2031, as highlighted in a new report published by Coherent
Market Insights.
Market key trends: One of the key trends driving the Pulmonary Edema
Therapeutics market is the development of new drug formulations and drug
delivery systems for improved treatment efficacy. For instance, companies are
focusing on developing controlled release or targeted delivery formulations of
diuretics and other drugs to ensure sustained release at the site of edema in
lungs. This helps maintain therapeutic drug levels for longer duration while
reducing administration frequency and side effects. Other trends include
development of combination therapies integrating diuretics with other classes
like vasodilators for synergistic effects. Further, companies are investing in
technologies like nanoparticle-based drug delivery to enhance localization of
drugs in the lungs for better management of pulmonary edema.
Porter's Analysis
Threat of new entrants: The threat is moderate as high capital investment is
required for R&D and clinical trials. However, the large unmet needs
provide opportunities.
Bargaining power of buyers: The bargaining power is moderate as the market
offers many generic products for treatment. However, branded drugs have some
pricing power.
Bargaining power of suppliers: The power is low to moderate as some generic
drug makers face supply issues during demand spikes. However, there are many
suppliers and alternatives.
Threat of new substitutes: The threat is low as no major substitute for drug
treatment exists. However, alternatives like oxygen therapy provide options.
Competitive rivalry: The rivalry is high among many players offering generic
and branded drugs. Innovation and portfolio expansion increase competition.
Key Takeaways
The Global
Pulmonary Edema Therapeutics Market Demand is
expected to witness high growth. The global Pulmonary Edema Therapeutics Market
is estimated to be valued at US$ 13990.01 Bn in 2024 and is expected to exhibit
a CAGR of 9.8% over the forecast period 2024 to 2031.
North
America dominates currently due to high healthcare spending and respiratory
disease prevalence. However, Asia Pacific is expected to be the fastest-growing
region due to rising healthcare investments, westernization, and expanding
patient base.
Key players operating in the pulmonary edema therapeutics market are Knoll
Inc., Freudenberg Group, Avgol Ltd., Carnegie Fabrics LLC, Eximius
Incorporation, Berry Global Group Inc., Asahi Kasei Corporation, Ahlstrom
Munksjo OYJ, Kimberly-Clark Corporation, and Paramount Tech Fab Industries,
among others. These players are focusing on portfolio expansion through
collaborations and M&As to strengthen their market presence.
For more details on the report, Read- https://www.insightprobing.com/pulmonary-edema-therapeutics-market-size-and-share/
Get
more insights on this topic: https://whotimes.com/beyond-dna-exploring-the-frontier-of-creation-through-the-lens-of-synthetic-biology/
Comments
Post a Comment